The CIRM partnership with Andelyn was established to advance BGTC’s mission to develop platforms and standards to propel the development and delivery of customised or bespoke’gene therapies for millions of people affected with rare diseases.
BGTC is focusing on development of cures for eight such diseases, with Andelyn selected to optimise and scale the AAV therapy processes for the treatment of Congenital Hereditary Endothelial Dystrophy – Type 1.
Matt Niloff, Chief Commercial Officer of Andelyn, said: “As a longstanding pioneer in AAV gene therapies and historical connection to the clinic, we have great synergies with the CIRM/BGTC."
"Andelyn is privileged to work with the CIRM/BGTC on its first AMP established specifically for rare disease and leverage our AAV Curator Platform to help overcome the major obstacles related to developing gene therapies.”
Dr Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM. said: "This partnership with Andelyn will enable progress in the field and help overcome manufacturing obstacles that can potentially lead to breakthroughs for rare diseases such as congenital hereditary endothelial dystrophy."
With exceptional quality and scalable end-to-end development and manufacturing capabilities across its three Columbus (OK, US) facilities, Andelyn is enabling the progression of life-altering gene therapies for rare and prevalent diseases.
